AstraZeneca says diabetes drug Farxiga fails in COVID-19 study
Reuters
Published Apr 12, 2021 07:22
Updated Apr 12, 2021 07:40
(Reuters) -AstraZeneca said on Monday primary data from a late-stage study to test whether its diabetes drug Farxiga could treat patients hospitalised with COVID-19, who are at risk of developing serious complications, did not meet its main goals.
The British drugmaker said Farxiga did not achieve statistical significance in cutting the risk of the disease worsening and death in such patients.
Farxiga was given over 30 days in a global trial of 1,250 patients hospitalised with COVID-19, in addition to the local standard of care.
Patients in the trial also had a medical history of hypertension, cardiovascular disease and heart failure, type-2 diabetes or chronic kidney disease.
AstraZeneca (NASDAQ:AZN) said the safety and tolerability profile for Farxiga at 30 days in the trial was consistent with established safety profile of the medicine.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.